Navigation Links
Jacobs Receives Contract From Gedeon Richter for New Biotechnology Facility in Hungary
Date:9/30/2008

PASADENA, Calif., Sept. 30 /PRNewswire-FirstCall/ -- Jacobs Engineering Group Inc. (NYSE: JEC) announced today that it received a contract from Gedeon Richter (BSE: GDRB) to provide engineering, procurement, and construction management services and validation assistance for a grassroots, multi-purpose biotechnology research & development and manufacturing facility in Debrecen, Hungary.

Officials did not disclose contract details but noted they would execute the work from their office in Milan, Italy.

Gedeon Richter, headquartered in Budapest, Hungary, is one of the largest multinational pharmaceutical companies in Central Eastern Europe and the Commonwealth of Independent States. It has a growing presence through commercial subsidiaries in key European Union countries, Asia, and the United States.

In making the announcement, Jacobs Group Vice President Robert Matha said "We are eager to help Gedeon Richter with this important project, which strengthens its commitment to biotechnology. In supporting the company's strategic goal of establishing a strong biopharma line, we also help Gedeon Richter to expand its worldwide portfolio of high value products."

Jacobs, with over 56,000 employees and revenues exceeding $10.0 billion, provides technical, professional, and construction services globally.

Any statements made in this release that are not based on historical fact are forward-looking statements. Although such statements are based on management's current estimates and expectations, and currently available competitive, financial, and economic data, forward-looking statements are inherently uncertain. We, therefore, caution the reader that there are a variety of factors that could cause business conditions
'/>"/>

SOURCE Jacobs Engineering Group Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Cepheid Receives FDA Clearance for First Rapid On-Demand Molecular Diagnostic Test for MRSA and S. aureus
2. Alexions Soliris(R) Receives 2008 Prix Galien USA Award for Best Biotechnology Product
3. Kuvan Receives Positive Opinion From CHMP for European Approval
4. Corgenix Receives Third U.S. Patent on AtherOx(R) Technology
5. Sustainable Oils Receives Regulatory Approval for Feeding Camelina Meal in Livestock Diets
6. U.S. Genomics Inc. Receives $4.5 Million Investment from BD
7. AdvanDx Receives FDA 510(k) Clearance for Yeast Traffic Light PNA FISH(TM)
8. PLC Systems Receives Delisting Notice From American Stock Exchange
9. Nephros Receives Non-Compliance Notification from AMEX
10. China Biologic Receives SFDA Approval for Clinical Trial of Human Coagulation Factor VIII
11. Barr Receives Approval for Generic Version of Razadyne(R) ER Capsules
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project 2Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer 2EUCODIS Bioscience Appoints Thomas Fischer as New CEO 2
Breaking Biology News(10 mins):Study shows nearly 1/3 of human genome is involved in gingivitis 2Study shows nearly 1/3 of human genome is involved in gingivitis 3The Academy of Natural Sciences and Temple Press revive rare natural history work in new book 2Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 2Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 3Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 4Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 5Stand Up to Cancer funds high-risk/high-reward cancer research by 13 young scientists 6Beneficial effects of alcohol 3F 59447 1Beneficial effects of alcohol 3F 59447 2Chimpanzees help each other on request but not voluntarily 10350 1Chimpanzees help each other on request but not voluntarily 10350 2Toms of Maine and charity 3A water Team Up to Fund Global Clean Water Projects With Instant Mobile Donation Campaign 59444 1Toms of Maine and charity 3A water Team Up to Fund Global Clean Water Projects With Instant Mobile Donation Campaign 59444 2Toms of Maine and charity 3A water Team Up to Fund Global Clean Water Projects With Instant Mobile Donation Campaign 59444 3